-

MindMed to Report Q3 2025 Financial Results on November 6, 2025

NEW YORK--(BUSINESS WIRE)--Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (the “Company” or “MindMed”), a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced that it will host a live webcast at 4:30 p.m. EST on Thursday, November 6, 2025 to report financial results for the third quarter ended September 30, 2025, and discuss recent business updates.

Listeners can register for the webcast via this link. Analysts wishing to participate in the question and answer session should use this link. A replay of the webcast will be available via the Investor Relations section of the MindMed website, ir.mindmed.co, and archived for at least 30 days after the webcast. Those who plan on participating are advised to join 15 minutes prior to the start time.

About MindMed

MindMed is a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders. Our mission is to be the global leader in the development and delivery of treatments that unlock new opportunities to improve patient outcomes. We are developing a pipeline of innovative product candidates, with and without acute perceptual effects, targeting neurotransmitter pathways that play key roles in brain health. MindMed trades on NASDAQ under the symbol MNMD.

Contacts

Investors:
Gitanjali Jain
VP, Head of Investor Relations
ir@mindmed.co

Media:
media@mindmed.co

Industry:

Mind Medicine (MindMed) Inc.

NASDAQ:MNMD
Release Versions
English

Contacts

Investors:
Gitanjali Jain
VP, Head of Investor Relations
ir@mindmed.co

Media:
media@mindmed.co

More News From Mind Medicine (MindMed) Inc.

Definium Therapeutics Reports Third Quarter 2026 Financial Results and Recent Highlights

NEW YORK--(BUSINESS WIRE)--Definium Therapeutics, Inc. (“Definium” or the “Company”) (NASDAQ: DFTX), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address underlying causes of psychiatric and neurological disorders, today reported financial results for the quarter ended September 30, 2026, and recent highlights. The Company also reported positive initial results from its Phase 2a trial of DT402 in adults with ASD, with improvements obser...

Definium Therapeutics Announces New Employee Inducement Grants

NEW YORK--(BUSINESS WIRE)--Definium Therapeutics, Inc. (“Definium” or the “Company”), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address underlying causes of psychiatric and neurological disorders, today announced the issuance of inducement grants to ten newly hired non-executive employees consisting of options to purchase an aggregate of 269,800 common shares of the Company (the "Options") with effective grant dates of November 9, 20...

Definium Therapeutics Presents Topline Phase 3 Data for DT120 ODT in Generalized Anxiety Disorder and Major Depressive Disorder at 2026 NEI Fall Congress

NEW YORK--(BUSINESS WIRE)--Definium Therapeutics, Inc. (Nasdaq: DFTX) (“Definium” or the “Company”), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address underlying causes of psychiatric and neurological disorders, today announced four poster presentations at the 2026 NEI Fall Congress taking place November 5 through 8 in Colorado Springs, CO. Positive topline results from Panorama, the Company’s second Phase 3 study of DT120 (lysergide...
Back to Newsroom